Literature DB >> 20544539

Identification of purine nucleoside phosphorylase deficiency in dried blood spots by a non-radiochemical assay using reversed-phase high-performance liquid chromatography.

A B P van Kuilenburg1, L Zoetekouw, J Meijer, T W Kuijpers.   

Abstract

Purine nucleoside phosphorylase (PNP) deficiency results in severe T cell dysfunction and hypouricemia. An assay to measure PNP activity in dried blood spots was developed using reversed-phase HPLC. The assay was linear with reaction times between 5 and 12.5 minutes, and protein concentrations ranging from 0.4 to 1.8 mg/ml. The intra-assay CV and the inter-assay CV for the complete assay was <3.6%. The PNP activity in a control blood spot, stored at 4 degrees C, remained stable for at least one year. In a patient suffering from a PNP deficiency, the residual PNP activity was only 0.3% compared to that observed in controls (1431 +/- 238 nmol/mg/h, n = 114). The PNP activity (483 +/- 35 nmol/mg/h, n = 3) in heterozygotes for the c.614A > C mutation (p.E205A) in the PNP gene was 34% compared to controls. Thus, the analysis of the PNP activity in blood spots can readily detect patients with a PNP deficiency.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544539     DOI: 10.1080/15257771003741455

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  2 in total

1.  Novel Genetic Mutations in the First Swedish Patient with Purine Nucleoside Phosphorylase Deficiency and Clinical Outcome After Hematopoietic Stem Cell Transplantation with HLA-Matched Unrelated Donor.

Authors:  Nicholas Brodszki; Maria Svensson; André B P van Kuilenburg; Judith Meijer; Lida Zoetekouw; Lennart Truedsson; Jacek Toporski
Journal:  JIMD Rep       Date:  2015-05-13

2.  Assessment of the red cell proteome of young patients with unexplained hemolytic anemia by two-dimensional differential in-gel electrophoresis (DIGE).

Authors:  Katharina von Löhneysen; Thomas M Scott; Katrin Soldau; Xiuling Xu; Jeffrey S Friedman
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.